Methods
Since July 2001, the senior author has followed with surveillance imaging UIAs felt to be at low risk for spontaneous subarachnoid hemorrhage (SAH) or UIAs whose risks of treatment outweigh the natural history. MR angiography (MRA) is the preferred imaging modality for aneurysm surveillance, which has been validated previously. 11, 26 CT angiography (CTA) or rarely digital subtraction angiography (DSA) were performed if contraindications to MRA existed. New images were compared with prior studies by the senior author and a staff radiologist. Only cases with a consensus opinion of growth or morphological change were considered positive. This surveillance protocol included MRA every 6 months for the first 2 years after diagnosis followed by annual MRA for 3 more years to complete 5 years of follow-up. After 5 years of stability, no further imaging was recommended.
Any increase in maximal diameter or a morphological change in the aneurysm was felt to indicate instability in the aneurysm wall, and this finding was usually followed with a recommendation for treatment. To account for delays in diagnosis of aneurysm growth or de novo aneurysm formation encountered with periodic imaging, a corrected time was also calculated as described by others. 18 The corrected time defined the date of aneurysm growth or de novo aneurysm formation as the date halfway between the imaging with the new finding and the previous imaging study.
To identify patients in aneurysm surveillance, medical records were retrospectively reviewed for patients initially evaluated from July 1, 2001 , to December 31, 2012 , with follow-up data reviewed through June 30, 2013 . This study had approval of the institutional review board. Case collection involved searching for patients seen in clinic with the diagnosis of an untreated UIA and at least 1 followup clinic visit or consultation. This yielded 342 patients. Manual chart review of these cases excluded 150 patients with 1) extradural aneurysms, 2) nonsaccular aneurysms, 3) aneurysms that had been treated, and 4) patients with fewer than 2 imaging studies. We identified 192 patients in aneurysm surveillance for further analysis.
Chart review of these patients involved documentation of reason for initial imaging, aneurysm location, aneurysm size, de novo aneurysms, sex, age at diagnosis, aspirin use, hypertension, tobacco smoking status (ever used tobacco or never used tobacco), history of cerebrovascular disease, family history of SAH, personal history of SAH, ethanol use, and illicit drug use. Since patients with a history of SAH were usually offered treatment instead of surveillance, only 2 surveilled patients had a history of SAH. Thus, statistical analysis was not performed for this risk factor. The aneurysm location was classified into internal carotid artery, posterior communicating artery, anterior communicating artery/anterior cerebral artery, middle cerebral artery, or "posterior" for vertebrobasilar and posterior cerebral artery aneurysms.
Final outcomes of surveillance were recorded. This included whether a patient remained compliant with the surveillance protocol. Medical records were reviewed for evidence of spontaneous SAH. If any treatment occurred, the type of treatment, angiographic result, and clinical outcome were documented.
statistical analysis
Logistic regression analyses for the 192 patients and 234 aneurysms were done separately with select explanatory variables for aneurysm growth or de novo aneurysm formation. Univariate logistic regression was performed to identify variables predicting aneurysm growth or de novo aneurysm formation for the following (values in parentheses represent the number of patients with missing data): age, sex, imaging reason, aspirin use (6), hypertension (6) , tobacco use (6), history of cerebrovascular disease (8) , family history of SAH (7), ethanol use (6) , and illicit drug use (6) . To identify aneurysm-specific variables predicting growth, univariate logistic regression was performed for the following (no missing data): aneurysms size, aneurysm location, and multiplicity. To identify variables predicting patient compliance to the aneurysm surveillance protocol, univariate logistic regression was performed for the following (missing data): age, sex, family history of SAH (7), tobacco use (6) , ethanol use (6) , and illicit drug use (6) . No model had multiple explanatory variables with p values < 0.20 in univariate analysis, so multivariate logistic regression analysis was not performed. Fisher's exact test was used to determine any association between patients with growth of UIAs and de novo aneurysm formation. Kaplan-Meier curves are presented for time to aneurysm growth as well as for time to either growth or de novo aneurysm formation (Figs. 1 and 2, respectively). Because our logistic regression analysis identified aneurysm size as a risk factor for growth, we performed a Kaplan-Meier analysis after stratifying aneurysms by size (< 5 mm and ≥ 5 mm) (Fig. 3) .
Odds ratios with 95% confidence intervals were calculated and are given in Table 1 for aneurysm growth; p values < 0.05 were considered significant. IBM SPSS Statistics (version 20) and SAS (version 9.3) software were used for statistical analysis.
literature search and study eligibility
We searched the PubMed database on August 1, 2014. The following search was performed: (cerebral OR intracranial) AND aneurysm AND (growth OR "de novo"). For the aneurysm growth literature review, retrospective or prospective series with at least 50 patients reporting patient number, aneurysm number, duration of follow-up, and number of growing aneurysms were included. The de novo aneurysm formation literature review included all retrospective or prospective series with at least 50 patients reporting number of patients, duration of follow-up, and number of de novo aneurysms. For series from the same institutions overlapping the same time period, the largest series were chosen. Titles and abstracts were reviewed to identify relevant articles. Reference lists of relevant studies were screened for additional relevant studies.
results
We evaluated 192 patients with 234 UIAs in our surveillance protocol. Baseline characteristics are presented in Table 1 . Excluding the initial imaging, there were 746 surveillance imaging studies with a mean of 3.9 studies per patient. The initial imaging modality was MRA in 73%, CTA in 20%, and DSA in 7%. Subsequent studies were MRA in 87%, CTA in 9%, and DSA in 4%. There was an average follow-up duration of 3.2 years per patient and 3.3 years per aneurysm, yielding 621 patient-years of follow-up and 793 aneurysm-years of follow-up. Seventyone percent of patients had at least 2 years of imaging follow-up.
overall surveillance results
During the surveillance period, growth was identified in 28 of 234 UIAs followed in 192 patients. Additionally, 4 de novo aneurysms formed over the same period. In 31 of 746 surveillance imaging studies, a growing aneurysm and/or de novo aneurysm was discovered (27 studies with growing aneurysms, 3 studies with de novo aneurysms, and 1 study with a growing aneurysm and a de novo aneurysm). These 31 events occurring during 621 patient-years of follow-up led to a 5.0% incidence of aneurysm growth or de novo aneurysm formation per patient-year of followup. Growth or de novo aneurysm formation at the 6-month examination was found in 10 patients (5.2%). The KaplanMeier curve in Fig. 1 illustrates the percentage of patients with a growing aneurysm or de novo aneurysm over time. The mean uncorrected time until growth or de novo aneurysm formation was 2.2 years (range 0.4-5.8 years) with a corrected time of 1.4 years (range 0.2-5.5 years).
aneurysm growth
The incidence of aneurysm growth per aneurysm-year of follow-up was 3.7%. No growth was seen in 206 aneurysms (88%), 10 aneurysms (4.3%) had early growth at the initial 6-month examination, 17 aneurysms (7.3%) had late growth, and 1 aneurysm grew at a late examination but did not have early imaging to rule out early growth. (Fig. 2 ). An enlargement in the maximum aneurysm diameter was seen in 25 aneurysms and a morphological change was seen in 3 aneurysms. The mean growth was 1.9 mm (range 0.7-6 mm).
Initial aneurysm size was the only predictor of aneurysm growth (p = 0.002) ( Table 1 ). The OR for continuous aneurysm size predicting aneurysm growth was 1.15 (95% CI 1.05-1.27) so that every 1-mm increase of initial aneurysm diameter increased the risk of growth during the protocol by 15%.The incidence of growth for UIAs < 5 mm versus UIA ≥ 5 mm was 1.6% and 8.7% per aneurysm-year, respectively (p = 0.002) (Fig. 3) .
De novo aneurysm Formation
Four of 192 patients developed de novo aneurysms during follow-up at an average uncorrected time until formation of 1.4 years (range 0.7-2.1 years) with a corrected time of 1.0 years (range 0.3-1.8 years). The incidence of de novo aneurysm formation per patient-year of follow-up was 0.64%. No patient-specific factor predicted de novo aneurysm formation. However, 3 of 4 patients with de novo aneurysms also had a growing aneurysm, and this was statistically significant (Fisher's exact, p = 0.01).
Protocol compliance, treatment outcomes, and occurrence of sah
Compliance with surveillance imaging was seen in 65% of patients. Older patients were less likely to be compliant with each additional year of age, decreasing compli- Treatment was undertaken in 22 of 32 growing or de novo aneurysms over 621 patient-years of follow-up (3.5% chance of treatment per patient-year of follow-up). Ten growing or de novo aneurysms were not treated because 4 patients declined treatment, 3 patients were of advanced age, 1 patient was too medically ill, 1 de novo aneurysm was deemed too small for treatment, and 1 de novo aneurysm was observed because the initial surveillance aneurysm was a stable basilar terminus aneurysm of higher risk. Of 22 patients receiving treatment, 7 underwent clip ligation and 15 received endovascular treatment. Twenty patients had a good neurological outcome with complete or near-complete aneurysm occlusion. One patient had partial monocular vision loss after embolization of an ophthalmic segment ICA aneurysm, and another patient died of a retroperitoneal hematoma after placement of a stent for staged treatment of a growing basilar terminus aneurysm.
Aneurysmal SAH occurred during follow-up in 1 patient and after completion of follow-up in another patient. The first patient was an 85-year-old man with a 14-mm basilar terminus aneurysm that was stable for 1.2 years into surveillance. He became noncompliant with imaging surveillance and presented 2.3 years after initial diagnosis with aneurysmal SAH. The other patient was a 66-yearold woman with a 10-mm basilar aneurysm that was stable on imaging for 4.7 years. She presented with SAH 3.5 years after completion of follow-up. Of note, both aneurysms were larger on their treatment DSA studies than on prior images.
Discussion
This report demonstrates a high rate of early growth in surveilled UIAs and much higher rate of growth in UIAs ≥ 5 mm. The study also demonstrates the feasibility of implementing an aneurysm surveillance protocol into practice for appropriately selected UIAs. The high rate of early growth in surveilled UIAs implicates that these lesions should be imaged more frequently during the initial surveillance period. Second, due to an increased incidence of growth for aneurysms ≥ 5 mm in diameter, these UIAs may warrant more frequent surveillance imaging, longer duration surveillance, or immediate occlusion. With these considerations, any recommendation regarding imaging frequency must balance costs and patient inconvenience with the risk of SAH due to an undetected growing UIA.
The concept of a growing aneurysm being unstable and posing a risk of imminent SAH has support from recent publications. These so-called "Yonekura type 2" aneurysms, are defined by growth immediately prior to rupture. 35 Inoue et al. found growing aneurysms that subsequently underwent surgical clipping to have walls that were "reddish, thin, and fragile" intraoperatively. 13 Frösen et al. have noticed similar thin hypocellular aneurysm walls (Type D) to be most common in ruptured aneurysms. 10 These same investigators suggest that loss of smooth muscle cells in the aneurysm wall underlies growth and subsequent rupture. The incidence of rupture from an acutely growing untreated UIA has been evaluated in 2 series in the literature. Inoue et al. cited an annual incidence of rupture in growing UIAs at 18.5%. Because some growing aneurysms were treated in their study (i.e., interrupting the natural history), the true risk of hemorrhage could be as high as 45%. Due to their use of low-resolution MRA, these investigators subselected very significantly enlarging UIAs. This accounted for the lower overall annual risk of growth (1.8%) with a very high annual incidence of rupture among growing UIAs (18.5%). 13 Villablanca et al. followed UIAs with CTA, a more sensitive methodology to detect growth. This highly sensitive method underlies their very high reported annual growth rate of 18%. Because they selected very subtly growing aneurysms, they found a lower annual risk of rupture of growing UIAs (2.4%). However, Villablanca et al. similarly found growing UIAs to be at higher risk of SAH. In their series, the risk of rupture in growing UIAs was 12-fold higher than the risk of rupture in nongrowing UIAs (2.4% vs 0.2%, p = 0.034).
31 These 2 studies highlight how the incidence of UIA growth or the incidence of rupture in Given that neither the patient-based data nor aneurysm-based data had 2 variables with a p value < 0.20, multivariate analysis was not performed for these models. † All statistical comparisons were made to stroke/transient ischemic attack, which had the lowest incidence of growth. ‡ All statistical comparisons were made to anterior communicating artery/anterior cerebral artery, which had the lowest incidence of growth. § Indicates vertebrobasilar and posterior cerebral artery aneurysms. ¶ p value calculated from continuous data from aneurysm size. growing UIAs can depend on the sensitivity of the imaging modality. More importantly, they strongly suggest that growing UIAs are unstable and are at higher risk for SAH than nongrowing UIAs. Based on the premise that growing UIAs are at higher risk of rupture, assessment of risk factors for aneurysm growth, especially modifiable risk factors, is clinically pertinent. The annual incidence of UIA growth is about 3.5% and the annual incidence of de novo aneurysm formation approaches 1% (Tables 2 and 3 ). As is evident from Table 2 , aneurysm size is the most consistent risk factor for aneurysm growth from the literature. We found larger aneurysm size to be the only predictor of aneurysm growth. Of 9 previous studies evaluating aneurysm size as a risk factor for aneurysm growth, 3 found that larger aneurysms grow more than smaller aneurysms (Table 2 ). These studies reported that UIAs larger than 5 mm, 8 mm, and 10 mm were more likely to grow. 4, 22, 24 We noted an increased risk of growth for aneurysms that are ≥ 5 mm (Fig. 3) . Since the risk of aneurysm rupture begins to increase at 7 mm, 5 mm may serve as a reasonable size to increase surveillance intensity or offer immediate treatment for aneurysm occlusion.
The ideal frequency of surveillance imaging for UIAs is not currently well defined.
3 Long-term frequent surveillance imaging is costly and burdensome to patients. However, the growth of aneurysms is likely nonlinear with episodic phases of growth being associated with high risks of SAH. 1, 6, 15, 19 We found the rate of growth at the 6-month examination to be much higher than expected. Using the multiplicative law of probability with an annual growth rate of 3.74%, and the occurrence of 6-month examination at 0.56 years, we find the expected incidence of aneurysm growth for a linear model would be 2.11%: However, 4.3% of aneurysms in our series grew as noted on the 6-month examination, suggesting more frequent early imaging is necessary to identify acutely growing UIAs for intervention to prevent SAH. Inoue et al. predicted that the likelihood of finding a growing aneurysm before rupture was 81.5% if evaluated every 12 months and 90.3% if evaluated every 6 months. 13 Given this much improved sensitivity with semiannual examinations and the higher than expected incidence of aneurysm growth seen at the 6-month examination in our protocol, it is our contention that future guidelines should recommend more frequent early surveillance imaging.
Modern treatment algorithms are beginning to define the natural history of specific aneurysms by the aneurysm location, aneurysm size, patient history of SAH, hypertension, and genetic risk factors.
12 New guidelines should also include documented growth during surveillance as a risk factor for aneurysm rupture. As more data are gained about the growth and formation of aneurysms, guidelines may begin to recommend treatment in younger patients if predictive modeling suggests an aneurysm is likely to grow and require treatment within a patient's lifetime. This model of treatment may save costs by foregoing years of unnecessary surveillance imaging for aneurysms that will be treated anyway, reduce morbidity by offering treatment to patients while they are younger with smaller aneurysms (both predictive of better treatment outcomes), and, most importantly, reduce the incidence of SAH.
34
Our study has several limitations. One limitation of this study is its retrospective design. Although the surveillance protocol was initiated in a prospective manner by the senior author, case selection and data collection were performed retrospectively. The imaging modalities and protocols used were nonuniform as was the interpretation of the new imaging studies by multiple radiologists. Long-term follow-up after completion of surveillance was not performed, meaning that some patients could have had delayed SAH undetected in this study. Lastly, almost the entire study population has no history of SAH and this should be acknowledged with comparison with other patient populations. 
